JP2002538170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002538170A5 JP2002538170A5 JP2000602303A JP2000602303A JP2002538170A5 JP 2002538170 A5 JP2002538170 A5 JP 2002538170A5 JP 2000602303 A JP2000602303 A JP 2000602303A JP 2000602303 A JP2000602303 A JP 2000602303A JP 2002538170 A5 JP2002538170 A5 JP 2002538170A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- administration
- antigen
- binding fragment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 239000012634 fragment Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 11
- 208000006673 asthma Diseases 0.000 description 9
- 229960000598 infliximab Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 229940116176 remicade Drugs 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 101100046526 Mus musculus Tnf gene Proteins 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26095399A | 1999-03-02 | 1999-03-02 | |
| US46569199A | 1999-12-17 | 1999-12-17 | |
| US09/260,953 | 1999-12-17 | ||
| US09/465,691 | 1999-12-17 | ||
| PCT/US2000/005163 WO2000051637A1 (en) | 1999-03-02 | 2000-03-01 | ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010195818A Division JP2011006464A (ja) | 1999-03-02 | 2010-09-01 | 喘息の治療における抗−ＴＮＦα抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002538170A JP2002538170A (ja) | 2002-11-12 |
| JP2002538170A5 true JP2002538170A5 (enExample) | 2010-10-28 |
Family
ID=26948290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000602303A Pending JP2002538170A (ja) | 1999-03-02 | 2000-03-01 | 喘息の治療における抗−ＴＮＦα抗体 |
| JP2010195818A Pending JP2011006464A (ja) | 1999-03-02 | 2010-09-01 | 喘息の治療における抗−ＴＮＦα抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010195818A Pending JP2011006464A (ja) | 1999-03-02 | 2010-09-01 | 喘息の治療における抗−ＴＮＦα抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20010021381A1 (enExample) |
| EP (1) | EP1159003B1 (enExample) |
| JP (2) | JP2002538170A (enExample) |
| AT (1) | ATE488250T1 (enExample) |
| AU (1) | AU756677B2 (enExample) |
| CA (1) | CA2364026C (enExample) |
| DE (1) | DE60045240D1 (enExample) |
| DK (1) | DK1159003T3 (enExample) |
| PT (1) | PT1159003E (enExample) |
| WO (1) | WO2000051637A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2341952A1 (en) | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| CA2515397A1 (en) * | 2003-02-11 | 2004-08-26 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies |
| WO2007120656A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| EP2084188A2 (en) | 2006-10-12 | 2009-08-05 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| EP2173380A4 (en) * | 2007-07-13 | 2011-08-31 | Abbott Biotech Ltd | METHOD AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa HEMMER |
| KR20120127543A (ko) | 2008-05-23 | 2012-11-21 | 시와 코퍼레이션 | 재생을 촉진하는 방법, 조성물 및 장치 |
| WO2012154253A1 (en) * | 2011-02-17 | 2012-11-15 | Prometheus Laboratories Inc. | ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFα DRUGS |
| RU2721568C2 (ru) * | 2014-09-19 | 2020-05-20 | Сива Корпорейшн | Анти-age антитела для лечения воспаления и аутоиммунных нарушений |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| CN109071675A (zh) | 2016-02-19 | 2018-12-21 | Siwa有限公司 | 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物 |
| CA3057829A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| EP3475306A1 (en) | 2016-06-23 | 2019-05-01 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| CN115804821B (zh) * | 2022-12-19 | 2024-05-14 | 新疆维吾尔药业有限责任公司 | 寒喘祖帕颗粒在制备治疗激素抵抗型哮喘药物中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309640B1 (en) * | 1981-09-08 | 2001-10-30 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| US4822776A (en) * | 1981-09-08 | 1989-04-18 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| US6419927B1 (en) * | 1981-09-08 | 2002-07-16 | Anthony Cerami | Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages |
| US4603106A (en) * | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| DE3888224T2 (de) * | 1987-04-24 | 1994-07-21 | Teijin Ltd | Bestimmung vom Tumornekrosefaktor; monoklonaler Antikörper und Zusammensetzung. |
| US5360716A (en) * | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
| US5223395A (en) * | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
| US5959087A (en) * | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
| GB8921123D0 (en) * | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
| AU8910891A (en) * | 1990-11-20 | 1992-06-11 | National Heart & Lung Institute, The | Treatment of lung diseases |
| GB9028123D0 (en) * | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| EP1097945B1 (en) * | 1991-03-18 | 2007-07-04 | New York University | Monoclonal and chimeric antibody specific for human tumor necrosis factor |
| US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| DE4139733A1 (de) * | 1991-11-28 | 1993-06-03 | Schering Ag | Carbacyclinderivate als mittel zur behandlung von krankheitsbildern, die zum atopie-kreis gehoeren |
| ATE155043T1 (de) * | 1992-10-08 | 1997-07-15 | Kennedy Inst Of Rheumatology | Behandlung von autoimmun- und entzundungskrankheiten |
| WO1994008609A1 (en) * | 1992-10-15 | 1994-04-28 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-α FUNCTION |
| GB9225448D0 (en) * | 1992-12-04 | 1993-01-27 | Erba Carlo Spa | Improved synthesis of polymer bioactive conjugates |
| US20050260201A1 (en) * | 1993-01-29 | 2005-11-24 | Centocor, Inc. | Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins |
| DE69427928T3 (de) * | 1993-03-05 | 2012-05-10 | Bayer Healthcare Llc | Humane monoklonale anti-TNF alpha Antikörper |
| SE9302490D0 (sv) * | 1993-07-26 | 1993-07-26 | Kabi Pharmacia Ab | New use of old drugs |
| GB9403909D0 (en) * | 1994-03-01 | 1994-04-20 | Erba Carlo Spa | Ureido derivatives of naphthalenephosphonic acids and process for their preparation |
| DE122004000004I1 (de) * | 1996-02-09 | 2004-08-12 | Abott Biotechnology Ltd | Humane Antikörper welche an Humanen TNFalpha binden. |
| GB9702088D0 (en) * | 1997-01-31 | 1997-03-19 | Pharmacia & Upjohn Spa | Matrix metalloproteinase inhibitors |
| ES2264569T3 (es) * | 1997-04-15 | 2007-01-01 | Pharmexa A/S | Moleculas de tnf-alfa modificadas, adn que codifica dichas moleculas de tnf-alfa modificadas y vacunas que comprenden dichas moleculas de tnf-alfa y adn. |
| JP2001525816A (ja) * | 1997-05-12 | 2001-12-11 | ザ ケネディー インスティチュート オブ リューマトロジー | 治療における腫瘍壊死因子アルファおよび血管内皮成長因子の抑制 |
-
2000
- 2000-03-01 AU AU33861/00A patent/AU756677B2/en not_active Ceased
- 2000-03-01 JP JP2000602303A patent/JP2002538170A/ja active Pending
- 2000-03-01 CA CA2364026A patent/CA2364026C/en not_active Expired - Fee Related
- 2000-03-01 PT PT00912065T patent/PT1159003E/pt unknown
- 2000-03-01 DK DK00912065.0T patent/DK1159003T3/da active
- 2000-03-01 AT AT00912065T patent/ATE488250T1/de active
- 2000-03-01 EP EP00912065A patent/EP1159003B1/en not_active Expired - Lifetime
- 2000-03-01 WO PCT/US2000/005163 patent/WO2000051637A1/en not_active Ceased
- 2000-03-01 DE DE60045240T patent/DE60045240D1/de not_active Expired - Lifetime
-
2001
- 2001-01-12 US US09/759,412 patent/US20010021381A1/en not_active Abandoned
- 2001-08-28 US US09/942,075 patent/US20020119152A1/en not_active Abandoned
-
2006
- 2006-03-02 US US11/366,724 patent/US20060222646A1/en not_active Abandoned
-
2010
- 2010-09-01 JP JP2010195818A patent/JP2011006464A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002538170A5 (enExample) | ||
| US6235281B1 (en) | Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 | |
| JP2011006464A (ja) | 喘息の治療における抗−ＴＮＦα抗体 | |
| JP4851645B2 (ja) | 抗−プロカルシトニン抗体、その調製および使用 | |
| US20030012786A1 (en) | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients | |
| Hamelmann et al. | Interleukin (IL)-5 but Not Immunoglobulin E Reconstitutes Airway Inflammation and Airway Hyperresponsiveness in IL-4–Deficient Mice | |
| JPH04507195A (ja) | 腫瘍壊死因子結合リガンド | |
| US20080317757A1 (en) | Human monoclonal antibody binding to hGM-CSF and its antigen binding portion | |
| AU2008251943A1 (en) | Humaneered anti-factor B antibody | |
| WO2002011677A2 (en) | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists | |
| JP2002539072A5 (enExample) | ||
| JP2004534513A5 (enExample) | ||
| CN103282384A (zh) | 复合药物组合物以及对泌尿生殖系统障碍进行治疗的方法 | |
| オオグシフミタカ et al. | Autoantibodies to IL-1α in sera from rapidly progressive idiopathic pulmonary fibrosis | |
| JP2002540771A (ja) | 抗体構築物およびケモカイン構築物ならびに自己免疫疾患の治療におけるそれらの使用 | |
| JPH06500323A (ja) | ウイルス性感染の治療方法 | |
| US20070048318A1 (en) | Method for treating psoriasis | |
| CN1189210C (zh) | Cb与生物活性多肽的偶联物及其医药用途 | |
| CA2730328C (en) | Immunogenic escherichia coli heat stable enterotoxin | |
| WO2005042028A2 (en) | Il-13 conjugated to an immunogen and uses thereof | |
| Wolff et al. | Human monoclonal antibody homodimers. Effect of valency on in vitro and in vivo antibacterial activity | |
| ES2357749T3 (es) | Anticuerpos anti-tnf alfa en la terapia del asma resistente a esteroides. | |
| US5674493A (en) | Compositions and methods for targeting cells with A2R and A2R monoclonal antibodies | |
| ES2256579T3 (es) | Anticuerpos que estimulan la produccion de 1l-1ra. | |
| US20210340226A1 (en) | Human medical prophylaxis of coronaviridae pathogenic infection by topical application of immune coronaviridae immunoglobulin a |